DOCSLIB.ORG

Building Bridges Forpatient CARE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Building Bridges Forpatient CARE 2016 REGISTRATION DOCUMENT 2016 REGISTRATION Building Bridges forPATIENT CARE 2016 REGISTRATION DOCUMENT SUMMARY GENERAL INTRODUCTORY COMMENTS 2 3 GROUP’S EMPLOYEES AND ENVIRONMENTAL ISSUES 135 3.1 Human resources 136 INTRODUCTION: KEY FIGURES 3 3.1.1 Group workforce 136 3.1.2 The Group’s Human Resources policy 138 1 PRESENTATION OF IPSEN AND ITS ACTIVITY 5 3.2 Environment, Health and Safety 140 1.1 Group’s overview and strategy 6 3.2.1 Regulatory Issues 140 1.1.1 History and Development of the Company 6 3.2.2 EHS Policy 141 3.2.3 EHS 2016 Performance 142 1.1.2 Group Strategy 8 3.2.4 Internal resources 151 1.2 Group’s activity and corporate structure 9 3.2.5 2016 Ipsen UN Global Compact Communication 1.2.1 The Group’s products 9 on Progress 151 1.2.2 Major Contracts 14 3.3 Social & societal information 154 1.2.3 Research and Development 18 3.3.1 Social relations 154 1.2.4 Intellectual Property 23 3.3.2 Societal information 155 1.2.5 Main Markets 25 4 CORPORATE GOVERNANCE 1.2.6 Regulations 26 AND LEGAL INFORMATION 165 1.2.7 The Group’s Legal Structure 27 4.1 Corporate governance 166 1.2.8 Risks Factors 28 4.1.1 Presentation of the Board of Directors and the Executive Committee 166 4.1.2 Reports of the Chairman of the Board 2 FINANCIAL INFORMATION OF THE COMPANY 39 and the Statutory Auditors 186 2.1 Management report for the financial year 40 4.1.3 Compensation of directors and officers 203 2.1.1 Significant events during the year 40 4.1.4 Agreements entered into by the Group with 2.1.2 Analysis of results 41 its senior executives or principal shareholders and Statutory Auditors’ Report 221 2.1.3 Net cash flow and financing 47 4.2 Information Related to the Company 2.1.4 Appendices 50 and its Share Capital 225 2.1.5 Subsequent events 56 4.2.1 Main Provisions of the Articles of Association 225 2.1.6 Group outlook 56 4.2.2 Share Capital 227 2.2 Consolidated financial statements 57 4.2.3 Shareholding 234 2.2.1 Consolidated income statement 57 5 ANNEXES 239 2.2.2 Consolidated balance sheet before allocation 5.1 Person responsible 240 of net profit 59 5.1.1 Attestation of the person responsible 2.2.3 Consolidated statement of cash flow 60 for the registration document 240 2.2.4 Statement of change in consolidated shareholders’ 5.1.2 Person responsible for financial information 240 equity 61 5.1.3 Person responsible for account audit and fees 240 2.2.5 Notes 63 5.2 Third party information, statements by experts 2.2.6 Statutory Auditors’ report on the consolidated and declarations of interests 241 financial statements 114 5.3 Consultation of legal documents 241 2.3 2016 Company financial statements 116 5.4 Components of the registration document, Board of directors’ report included in the registration 2.3.1 Summary document 116 document and Annual Financial Report 241 2.3.2 Notes to the annual financial statements 118 5.4.1 Component of the Annual Financial Report 241 2.3.3 Statutory Auditor’s Report on the annual financial 5.4.2 Correspondence table for the registration document 242 statements 131 2.3.4 Information related to Ipsen’s business activity 132 6 INDEX 247 This registration document has been established in accordance with the Appendix 1 of the European Commission Regulation n°809/2004 dated April 29, 2004. Société anonyme with a share capital of 83,580,494 euros Registered office: 65 quai Georges Gorse – 92650 Boulogne-Billancourt 419 838 529 R.C.S. Nanterre 2016 REGISTRATION DOCUMENT Pursuant to the provisions of its general regulations, in particular article 212-13, the Autorité des Marchés Financiers (AMF) has registered this registration document on 27 March 2017, under number D.17-0231. This document may not be used in support of any financial operation unless it is accompanied by a prospectus approved by the AMF. This document has been prepared by the issuer, and its signatories assume responsibility for its contents. Pursuant to the provisions of article 28 of EC regulation 809/2004 of 29 April 2004, readers are referred to the Document de Référence for Ipsen recorded by the AMF on 29 March 2016 under number D.16-0216 for the 2015 financial year and on 27 March 2015 under number D.15-0221 for the 2014 financial year, for the following financial information, prepared under IFRS (International Financial Reporting Standard): historical and consolidated financial statement (including the auditors’ reports). GENERAL INTRODUCTORY COMMENTS In this registration document, unless stated otherwise, Investors are urged to pay careful attention to the risk factors the terms “Company” and “Ipsen” refer to Ipsen S.A. and described in paragraphs 1.2.8.1, 1.2.8.2, 1.2.8.3, 1.2.8.4, the term “Group” refers to Ipsen and its subsidiaries and 1.2.8.5 and 1.2.8.6 of this registration document before shareholdings. making their investment decision. One or more of these risks may have an adverse effect on the Group’s activities, This registration document contains forward-looking condition, results of operations or on its targets and forecasts. statements about the Group’s targets and forecasts, especially Furthermore, other risks not yet identified or considered as in Chapter 2.1.4. Such statements may in certain cases be significant by the Group could have the same adverse effects, identified by the use of the future or conditional tense or by and investors may lose all or part of their investment. forward-looking words including but not limited to “believes”, This registration document also contains details of the markets “targets”, “anticipates”, “intends”, “should”, “aims”, “estimates”, in which the Group operates. This information is notably taken “considers”, “wishes” and “may”. These statements are based from research produced by external organizations. Given the on data, assumptions and estimates that the Company very rapid pace of change in the pharmaceutical sector in considers to be reasonable. They are subject to change or France and the rest of the world, this information may prove to adjustment owing to uncertainties arising from the vagaries be erroneous or out of date. inherent in all research and development activities, as well as in the economic, financial, competitive, regulatory and climatic Forward-looking statements, targets and forecasts shown in environment. In addition, the Group’s business activities and this registration document may be affected by risks, either its ability to meet its targets and forecasts may be affected known or unknown, uncertainties or other factors that may if certain of the risk factors described in Chapter 1.2.8 – lead to the Group’s future results of operations, performance “Risk factors” of this registration document arise. In addition, and achievements differing significantly from the stated or attainment of the targets and forecasts implies the success implied targets and forecasts. These factors may include of the strategy presented in section 1.1.2 – “Strategy” of this changes in economic or trading conditions and regulations, registration document. as well as the factors set forth in Chapter 1.2.8 – “Risk factors” of this registration document. The Company makes no undertaking and gives no guarantee as to attainment of the targets and forecasts shown in this registration document. 2 2016 Ipsen Registration document INTRODUCTION: KEY FIGURES 2016 Group sales by therapeutic areas 2016 Group sales by geographic areas Specialty Major Western Care Oncology European Other 80.3% 57.1% countries European 36.1% Countries 22.0% Endocrinology 5.1% Neurosciences 18.1% Primary Care North America Rest of the World 19.7% 17.2% 24.7% Core Operating Income (in millions of euros)(1) Core consolidated net profit (in millions of euros)(1) 364 328 264 234 2015 2016 2015 2016 Ownership of the Company’s share capital Dividend per share paid for the financial year (in euros) at 31 December 2016 0.85 0.85 FCPE Mayroy SA 0.2% 56.6% Treasury shares 1.4% Other registered shareholders 0.9% Directors Free Float (ex. Mayroy SA) 2015 2016 40.7% 0.2% (1) New definition of Core financial measures which excludes amortization of intangible assets (excluding software), gain or loss on disposal of fixed assets, restructuring costs, impairment losses and other non-core items. 2016 Ipsen Registration document 3 INTRODUCTION: KEY FIGURES Share price performance on the stock exchange Ipsen shares joined the Deferred Settlement System on Shares in Ipsen S.A. have been traded on the Eurolist by 28 March 2007. Euronext™ market (Compartment A) since 7 December 2005, Ipsen has implemented a Sponsored Level I American € when the IPO (Initial Public Offering) price was 22.20 per Depositary Receipt (ADR) program and trades on the over- share. the-counter market in the United States under the symbol Ipsen shares joined the SBF120 index on 24 December 2007. IPSE Y. Share information 2016 trading data ISIN Code FR0010259150 Average share price €56.8 Euronext Code IPN.PA Highest price (29/12/2016) €69.0 ADR Code IPSEY Lowest price (21/03/2016) €47.1 SRD / PEA Eligibility Yes / Yes Stock market capitalization(1) €5,740.4M Total Shares(1) 83.6 M Average daily volume 82,393.0 (1) As of 31 December 2016. Comparison between Ipsen’s share price performance and the principal stock market indicators between 4 January 2016 and 30 December 2016 (Source: Reuters) Price (€) Volume 75 1,000,000 70 800,000 65 600,000 60 55 400,000 50 200,000 45 40 0 July 16 July 16 May 16 May 16 April 16 June 16 March 16 March 16 August 16 August 16 January 16 January 16 October 16 October 16 February 16 December 16 December 16 November 16 September 16 Volume
Load more

Recommended publications
  • ———— 2016 Registration Document
    ———— 2016 REGISTRATION DOCUMENT Including the annual financial report 01 Persons responsible 3 16 Practices of the governing bodies 91 02 Statutory Auditors 5 17 Employees 93 17.1 Employee data 93 03 Selected financial information 7 17.2 Employee share-ownership and profit-sharing 95 04 Risks 11 18 Major shareholders 97 4.1 Risks specific to the Group’s activity 11 18.1 Shareholders and their voting rights 98 4.2 Liquidity risk 14 18.2 Transactions carried out 4.3 Interest rate risk 15 during the year subject to 4.4 Exchange-rate risk 16 Article L. 621-18-2 of the French 4.5 Intangible asset risk 16 Monetary and Financial Code 100 contents 4.6 Environment risk 17 18.3 Share buybacks 101 4.7 Legal and fiscal risks 17 18.4 Market for Altran Technologies securities 102 4.8 Investment risk 17 18.5 Information on the calculation methods 4.9 Brexit risk 18 and effects of adjustments to the conditions covering the subscription or 05 Company information 19 purchase of rights and securities giving 5.1 Company background information and access to the Company’s share capital 103 development 19 18.6 Agreements entered into by the 5.2 Main investments 20 Company which would be amended or terminated upon a change of control of 06 Information about the the Company 103 Group’s businesses 21 18.7 Agreements between shareholders, of 6.1 Core activities 21 which the Company is aware and which may cause restrictions to the transfer of 6.2 The Engineering and R&D Services market 22 shares and/or the exercise of voting rights 104 6.3 Competition 24 18.8 Commitments
    [Show full text]
  • The Epistemology of Evidence in Cognitive Neuroscience1
    To appear in In R. Skipper Jr., C. Allen, R. A. Ankeny, C. F. Craver, L. Darden, G. Mikkelson, and R. Richardson (eds.), Philosophy and the Life Sciences: A Reader. Cambridge, MA: MIT Press. The Epistemology of Evidence in Cognitive Neuroscience1 William Bechtel Department of Philosophy and Science Studies University of California, San Diego 1. The Epistemology of Evidence It is no secret that scientists argue. They argue about theories. But even more, they argue about the evidence for theories. Is the evidence itself trustworthy? This is a bit surprising from the perspective of traditional empiricist accounts of scientific methodology according to which the evidence for scientific theories stems from observation, especially observation with the naked eye. These accounts portray the testing of scientific theories as a matter of comparing the predictions of the theory with the data generated by these observations, which are taken to provide an objective link to reality. One lesson philosophers of science have learned in the last 40 years is that even observation with the naked eye is not as epistemically straightforward as was once assumed. What one is able to see depends upon one’s training: a novice looking through a microscope may fail to recognize the neuron and its processes (Hanson, 1958; Kuhn, 1962/1970).2 But a second lesson is only beginning to be appreciated: evidence in science is often not procured through simple observations with the naked eye, but observations mediated by complex instruments and sophisticated research techniques. What is most important, epistemically, about these techniques is that they often radically alter the phenomena under investigation.
    [Show full text]
  • Liste Des Actions Concernées Par L'interdiction De Positions Courtes Nettes
    Liste des actions concernées par l'interdiction de positions courtes nettes L’interdiction s’applique aux actions listées sur une plate-forme française et relevant de la compétence de l’AMF au titre du règlement 236/2012 (information disponible dans les registres ESMA). Cette liste est fournie à titre informatif. L'AMF n'est pas en mesure de garantir que le contenu disponible est complet, exact ou à jour. Compte tenu des diverses sources de données sous- jacentes, des modifications pourraient être apportées régulièrement. Isin Nom FR0010285965 1000MERCIS FR0013341781 2CRSI FR0010050773 A TOUTE VITESSE FR0000076887 A.S.T. GROUPE FR0010557264 AB SCIENCE FR0004040608 ABC ARBITRAGE FR0013185857 ABEO FR0012616852 ABIONYX PHARMA FR0012333284 ABIVAX FR0000064602 ACANTHE DEV. FR0000120404 ACCOR FR0010493510 ACHETER-LOUER.FR FR0000076861 ACTEOS FR0000076655 ACTIA GROUP FR0011038348 ACTIPLAY (GROUPE) FR0010979377 ACTIVIUM GROUP FR0000053076 ADA BE0974269012 ADC SIIC FR0013284627 ADEUNIS FR0000062978 ADL PARTNER FR0011184241 ADOCIA FR0013247244 ADOMOS FR0010340141 ADP FR0010457531 ADTHINK FR0012821890 ADUX FR0004152874 ADVENIS FR0013296746 ADVICENNE FR0000053043 ADVINI US00774B2088 AERKOMM INC FR0011908045 AG3I ES0105422002 AGARTHA REAL EST FR0013452281 AGRIPOWER FR0010641449 AGROGENERATION CH0008853209 AGTA RECORD FR0000031122 AIR FRANCE -KLM FR0000120073 AIR LIQUIDE FR0013285103 AIR MARINE NL0000235190 AIRBUS FR0004180537 AKKA TECHNOLOGIES FR0000053027 AKWEL FR0000060402 ALBIOMA FR0013258662 ALD FR0000054652 ALES GROUPE FR0000053324 ALPES (COMPAGNIE)
    [Show full text]
  • Outlook Magazine, Autumn 2018
    Washington University School of Medicine Digital Commons@Becker Outlook Magazine Washington University Publications 2018 Outlook Magazine, Autumn 2018 Follow this and additional works at: https://digitalcommons.wustl.edu/outlook Recommended Citation Outlook Magazine, Autumn 2018. Central Administration, Medical Public Affairs. Bernard Becker Medical Library Archives. Washington University School of Medicine, Saint Louis, Missouri. https://digitalcommons.wustl.edu/outlook/188 This Article is brought to you for free and open access by the Washington University Publications at Digital Commons@Becker. It has been accepted for inclusion in Outlook Magazine by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. AUTUMN 2018 Elevating performance BERNARD BECKER MEDICAL LIBRARY BECKER BERNARD outlook.wustl.edu Outlook 3 Atop the Karakoram Mountains, neurologist Marcus Raichle, MD, (center) displays a Mallinckrodt Institute of Radiology banner he created. In 1987, he and other members of a British expedition climbed 18,000 feet above sea level — and then injected radioactive xenon to see how it diffused through their brains. Raichle, 81, has been a central force for decades in the history and science of brain imaging. See page 7. FEATURES MATT MILLER MATT 7 Mysteries explored Pioneering neurologist Marcus Raichle, MD, opened up the human brain to scientific investigation. 14 Growing up transgender The Washington University Transgender Center helps families navigate the complex world of gender identity. COVER Scott Brandon, who sustained a spinal cord injury 16 years ago, said he is 21 Building independence grateful to the Program in Occupational For 100 years, the Program in Occupational Therapy has Therapy for helping him build physical and helped people engage mind and body.
    [Show full text]
  • Actions Synthétiques France Heures De Négociation : 9:00 - 17:30 (CET) Frais Et Commissions : 0.1% Du Montant De La Transaction, Min
    Actions Synthétiques France Heures de négociation : 9:00 - 17:30 (CET) Frais et Commissions : 0.1% du montant de la transaction, min. 8 EUR (Marge sur commission: 70% - 99.9%). Symbole Instrument dont le prix est basé sur Nombre d'actions par lot Taille minimale d'un ordre en lots Vente à découvert Taux d'emprunt de titre (%) AC.FR Accor SA CFD 1 1 OUI -3 ACA.FR Credit Agricole SA CFD 1 1 OUI -3 ADP.FR Aeroports de Paris CFD 1 1 OUI -3 AF.FR Air France-KLM CFD 1 1 OUI -3 AI.FR Air Liquide SA CFD 1 1 OUI -3 AIR.FR Airbus Group NV CFD 1 1 NON - AKE.FR Arkema SA CFD 1 1 OUI -3 ALO.FR Alstom SA CFD 1 1 OUI -3 ALT.FR Altran Technologies SA CFD 1 1 OUI -3 ATO.FR AtoS CFD 1 1 OUI -3 BB.FR Societe BIC SA CFD 1 1 OUI -3 BIM.FR BioMerieux CFD 1 1 OUI -3 BN.FR Danone CFD 1 1 OUI -3 BNP.FR BNP Paribas CFD 1 1 OUI -3 BOL.FR Bollore SA CFD 1 1 OUI -3 BVI.FR Bureau Veritas SA CFD 1 1 OUI -3 CA.FR Carrefour SA CFD 1 1 OUI -3 CAP.FR Cap Gemini SA CFD 1 1 OUI -3 CGG.FR CGG SA CFD 1 1 NON - CNP.FR CNP Assurances CFD 1 1 OUI -3 CO.FR Casino Guichard Perrachon SA CFD 1 1 OUI -3 COFA.FR Coface SA CFD 1 1 OUI -4,5 CS.FR AXA SA CFD 1 1 OUI -3 DEC.FR JCDecaux SA CFD 1 1 OUI -3 DG.FR Vinci SA CFD 1 1 OUI -3 DSY.FR Dassault Systemes CFD 1 1 OUI -3 EDEN.FR Edenred CFD 1 1 OUI -3 EDF.FR EDF SA CFD 1 1 OUI -3 EI.FR Essilor International SA CFD 1 1 OUI -3 ELE.FR Euler Hermes Group CFD 1 1 OUI -4,5 EN.FR Bouygues SA CFD 1 1 OUI -3 ENGI.FR ENGIE CFD 1 1 OUI -3 ENX.FR Euronext NV CFD 1 1 OUI -3 EO.FR Faurecia CFD 1 1 OUI -3 ERA.FR Eramet CFD 1 1 OUI -5 ERF.FR Eurofins
    [Show full text]
  • Mersen Urd 2020
    URD 2020 Universal Registration Document MERSEN Universal Registration Document page 1 Group Profile 3 2 Corporate governance report 17 3 Management Report 75 4 Social responsibility and sustainable development 101 5 Information about the share capital and share ownership 147 6 Consolidated financial statements 165 7 Parent company financial statements 225 8 Additional information & glossaries 253 This document is a free translation into English for convenience purposes only of the French URD fi led with the Autorité des Marchés Financiers on March 15, 2021. URD 2020 | MERSEN 1 2 MERSEN | URD 2020 1 GROUP PROFILE 2020: AN UNPRECEDENTED YEAR 5 2020 KEY FIGURES 6 GROUP B USINESS M ODEL 8 VISION, MISSION AND VALUES 10 URD 2020 | MERSEN 3 GROUP PROFILE 1 4 MERSEN | URD 2020 GROUP PROFILE 2020: an unprecedented year 1 2020: AN UNPRECEDENTED YEAR After several years of growth, the Covid-19 pandemic hit the The additional direct costs caused by Covid-19 (purchase of global economy hard in 2020, with many countries introducing masks, cleaning costs, exceptional transportation, etc.) were travel restrictions, lockdown measures and quarantines to slow recorded but were for the most part offset by decreased spending the spread of the pandemic. These restrictions began in January as a result of slower business activity (especially reduced travel and February in China and then reached Europe in early March expenses). and America at the end of March. All in all, the Group demonstrated its resilience and ability to adapt Although some countries eased their lockdowns after the fi rst its expenditure, delivering operating margin of 8.1% of sales.
    [Show full text]
  • FALL 2018 MSK Takes a Lead Role in Interventional Oncology FSFOCAL
    FOCAL SPOT FS FALL 2018 MSK Takes a Lead Role in Interventional Oncology MALLINCKRODT INSTITUTE OF RADIOLOGY // WASHINGTON UNIVERSITY // ST. LOUIS CONTENTS 10 A look at 10 MIR professors RAD who are helping lead the way for women in radiology. (From left: Geetika Khanna, MD, Pamela K. WOMEN Woodard, MD, and Farrokh Dehdashti, MD) 6 16 20 LIFE-ALTERING MYSTERIES MIR ALUMNI TREATMENT EXPLAINED WEEKEND MSK imaging chief Jack Jennings, Thirty years later, Marcus E. Raichle, Old friends, new stories and a sweet MD, provides quality-of-life improving MD, remains a central figure in the serenade from Ronald G. Evens, MD. procedures for patients with cancer. science of brain imaging. Inside MIR’s first reunion. Cover Photo: Metastatic melanoma patient Chris Plummer still works his farm every day, thanks to treatment resulting in unprecedented control of his tumors. 2 SPOT NEWS 24 ALUMNI SPOTLIGHT FOCAL SPOT MAGAZINE FALL 2018 Editor: Marie Spadoni Photography: Mickey Wynn, Daniel Drier Design: Kim Kania YI F A LOOK BACK ©2018 Mallinckrodt Institute of Radiology 26 28 mir.wustl.edu FOCAL SPOT MAGAZINE // 1 SPOT NEWS David H. Ballard, MD, a TOP-TIER participant, uses 3D printing in his translational imaging work. Training the Next Generation of Imaging Scientists by Kristin Rattini For young scientists eager to make their way to the forefront in clinical translational imaging research and bringing of translational research and precision imaging, Mallinckrodt innovation to the practice of medicine. The interdisciplinary Institute of Radiology (MIR) offers a clear path. A leader in grant provides two training slots per year in years one NIH funding, MIR is home to premier training programs and and two, and three slots in years three through five.
    [Show full text]
  • Amundi Actions Pme
    SEMI-ANNUAL REPORT OCTOBER 2019 AMUNDI ACTIONS PME AMUNDI’S ASSET MANAGEMENT UCITS Fund manager Amundi Asset Management Delegated fund accountant CACEIS Fund Administration France Custodian CACEIS BANK Auditors PRICEWATERHOUSECOOPERS AUDIT UCITS AMUNDI ACTIONS PME Statement of Net Assets in EUR Elements of Statement of Net Assets Semi-Annual Report Amounts* a) Eligible financial securities mentioned in paragraph 1 of section I of Article L. 214-20 of the French 661,050,287.17 Monetary and Financial Code. b) Cash at banks and liquidities 3,919,900.98 c) Other Assets held by the UCITS 72,513,792.08 d) Total of Assets held by the UCITS (lines a+b+c) 737,483,980.23 e) Liabilities -991,745.75 f) Net Asset Value (lines d+e= net asset of the UCITS) 736,492,234.48 * Amounts are signed Number of units or shares outstanding and net asset values per unit or share Number of units Net asset value per Unit Unit type Net Assets per unit outstanding share AMUNDI ACTIONS PME C C 447,179,434.24 640,726.857 697.92 AMUNDI ACTIONS PME 0 C 203,327,023.30 1,093,251.672 185.98 AMUNDI ACTIONS PME S C 85,985,776.94 123,651.972 695.38 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Semi-Annual Report on 10/31/19 2 UCITS AMUNDI ACTIONS PME Items of portfolio listing Total Percentage of Items of portfolio listing Percentage Net Assets * Assets ** A) Eligible financial securities and money market instruments admitted for trading 89.76 89.64 on a regulated market pursuant to Article L.
    [Show full text]
  • Reviewers [PDF]
    The Journal of Neuroscience, January 2013, 33(1) Acknowledgement For Reviewers 2012 The Editors depend heavily on outside reviewers in forming opinions about papers submitted to the Journal and would like to formally thank the following individuals for their help during the past year. Kjersti Aagaard Frederic Ambroggi Craig Atencio Izhar Bar-Gad Esther Aarts Céline Amiez Coleen Atkins Jose Bargas Michelle Aarts Bagrat Amirikian Lauren Atlas Steven Barger Lawrence Abbott Nurith Amitai David Attwell Cornelia Bargmann Brandon Abbs Yael Amitai Etienne Audinat Michael Barish Keiko Abe Martine Ammasari-Teule Anthony Auger Philip Barker Nobuhito Abe Katrin Amunts Vanessa Auld Neal Barmack Ted Abel Costas Anastassiou Jesús Avila Gilad Barnea Ute Abraham Beau Ances Karen Avraham Carol Barnes Wickliffe Abraham Richard Andersen Gautam Awatramani Steven Barnes Andrey Abramov Søren Andersen Edward Awh Sue Barnett Hermann Ackermann Adam Anderson Cenk Ayata Michael Barnett-Cowan David Adams Anne Anderson Anthony Azevedo Kevin Barnham Nii Addy Clare Anderson Rony Azouz Scott Barnham Arash Afraz Lucy Anderson Hiroko Baba Colin J. Barnstable Ariel Agmon Matthew Anderson Luiz Baccalá Scott Barnum Adan Aguirre Susan Anderson Stephen Baccus Ralf Baron Geoffrey Aguirre Anuska Andjelkovic Stephen A. Back Pascal Barone Ehud Ahissar Rodrigo Andrade Lars Bäckman Maureen Barr Alaa Ahmed Ole Andreassen Aldo Badiani Luis Barros James Aimone Michael Andres David Badre Andreas Bartels Cheryl Aine Michael Andresen Wolfgang Baehr David Bartés-Fas Michael Aitken Stephen Andrews Mathias Bähr Alison Barth Elias Aizenman Thomas Andrillon Bahador Bahrami Markus Barth Katerina Akassoglou Victor Anggono Richard Baines Simon Barthelme Schahram Akbarian Fabrice Ango Jaideep Bains Edward Bartlett Colin Akerman María Cecilia Angulo Wyeth Bair Timothy Bartness Huda Akil Laurent Aniksztejn Victoria Bajo-Lorenzana Marisa Bartolomei Michael Akins Lucio Annunziato David Baker Marlene Bartos Emre Aksay Daniel Ansari Harriet Baker Jason Bartz Kaat Alaerts Mark S.
    [Show full text]
  • Présentation Powerpoint
    Capital Markets Day December 1, 2020 1 Disclaimer & Safe Harbor • This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new product can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons. The Group must deal with or may have to deal with competition from generic that may result in market share losses, which could affect its current level of growth in sales or profitability. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law. • All product names listed in this document are either licensed to the Ipsen Group or are registered trademarks of the Ipsen Group or its partners. • The implementation of the strategy has to be submitted to the relevant staff representation authorities in each country concerned, in compliance with the specific procedures, terms and conditions set forth by each national legislation.
    [Show full text]
  • Uva-DARE (Digital Academic Repository)
    UvA-DARE (Digital Academic Repository) The space inside the skull : digital representations, brain mapping and cognitive neuroscience in the decade of the brain Beaulieu, J.A. Publication date 2000 Link to publication Citation for published version (APA): Beaulieu, J. A. (2000). The space inside the skull : digital representations, brain mapping and cognitive neuroscience in the decade of the brain. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:30 Sep 2021 Workss Cited Ahhot.. Allison 19922 Confusion about form and function clouds launch of EC's Decade of ihe Brain. Nature. 24 September.. 359: 260. Ackerman.. Sandra 19922 The Role of the Brain in Mental Illness. !n Discovering the Brain. 46-66. Washington. DC:: National Academy Press.
    [Show full text]
  • Giovanni Berlucchi
    BK-SFN-NEUROSCIENCE-131211-03_Berlucchi.indd 96 16/04/14 5:21 PM Giovanni Berlucchi BORN: Pavia, Italy May 25, 1935 EDUCATION: Liceo Classico Statale Ugo Foscolo, Pavia, Maturità (1953) Medical School, University of Pavia, MD (1959) California Institute of Technology, Postdoctoral Fellowship (1964–1965) APPOINTMENTS: University of Pennsylvania (1968) University of Siena (1974) University of Pisa (1976) University of Verona (1983) HONORS AND AWARDS: Academia Europaea (1990) Accademia Nazionale dei Lincei (1992) Honorary PhD in Psychology, University of Pavia (2007) After working initially on the neurophysiology of the sleep-wake cycle, Giovanni Berlucchi did pioneering electrophysiological investigations on the corpus callosum and its functional contribution to the interhemispheric transfer of visual information and to the representation of the visual field in the cerebral cortex and the superior colliculus. He was among the first to use reaction times for analyzing hemispheric specializations and interactions in intact and split brain humans. His latest research interests include visual spatial attention and the representation of the body in the brain. BK-SFN-NEUROSCIENCE-131211-03_Berlucchi.indd 97 16/04/14 5:21 PM Giovanni Berlucchi Family and Early Years A man’s deepest roots are where he has spent the enchanted days of his childhood, usually where he was born. My deepest roots lie in the ancient Lombard city of Pavia, where I was born 78 years ago, on May 25, 1935, and in that part of the province of Pavia that lies to the south of the Po River and is called the Oltrepò Pavese. The hilly part of the Oltrepò is covered with beautiful vineyards that according to archaeological and historical evidence have been used to produce good wines for millennia.
    [Show full text]